Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.

ABSTRACT:

Purpose

To evaluate the outcomes of intravitreal bevacizumab (IVB) use in patients with a vitreous hemorrhage (VH) secondary to proliferative diabetic retinopathy (PDR).

Design

Retrospective, interventional case series.

Methods

Patients who presented to Scheie Eye Institute between January 2008 and January 2015 with a new VH secondary to PDR and treated with IVB were included. Exclusion criteria consisted of IVB treatment prior to the study, a history of pars plana vitrectomy (PPV), and less than 1 year of follow-up. Outcomes of interest were additional treatments including PPV, injections, and panretinal photocoagulation (PRP), as well as visual acuity at baseline and at 1 year.

Results

Of the 111 eligible eyes, 55 (49.5%) had PRP, 35 (31.6%) were managed with

SUBMITTER: Parikh RN 

PROVIDER: S-EPMC5376507 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature